376 related articles for article (PubMed ID: 20502723)
21. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB; Strober B; Lebwohl M; Augustin M; Blauvelt A; Poulin Y; Papp KA; Sofen H; Puig L; Foley P; Ohtsuki M; Flack M; Geng Z; Gu Y; Valdes JM; Thompson EHZ; Bachelez H
Lancet; 2018 Aug; 392(10148):650-661. PubMed ID: 30097359
[TBL] [Abstract][Full Text] [Related]
23. Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.
Schafer JA; Kjesbo NK; Gleason PP
J Manag Care Pharm; 2010; 16(6):402-16. PubMed ID: 20635831
[TBL] [Abstract][Full Text] [Related]
24. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
[TBL] [Abstract][Full Text] [Related]
25. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.
Croxtall JD
Drugs; 2011 Sep; 71(13):1733-53. PubMed ID: 21902296
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
Leonardi CL; Kimball AB; Papp KA; Yeilding N; Guzzo C; Wang Y; Li S; Dooley LT; Gordon KB;
Lancet; 2008 May; 371(9625):1665-74. PubMed ID: 18486739
[TBL] [Abstract][Full Text] [Related]
28. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
[TBL] [Abstract][Full Text] [Related]
29. Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.
Wang SH; Chi CC; Hu S
Int J Dermatol; 2014 Sep; 53(9):1151-6. PubMed ID: 24738910
[TBL] [Abstract][Full Text] [Related]
30. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
31. Comparing biological therapies in psoriasis: implications for clinical practice.
Griffiths CE
J Eur Acad Dermatol Venereol; 2010 Oct; 24 Suppl 6():10-4. PubMed ID: 20831704
[TBL] [Abstract][Full Text] [Related]
32. Ustekinumab.
Weber J; Keam SJ
BioDrugs; 2009; 23(1):53-61. PubMed ID: 19344192
[TBL] [Abstract][Full Text] [Related]
33. Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis.
Scanlon JV; Exter BP; Steinberg M; Jarvis CI
Ann Pharmacother; 2009 Sep; 43(9):1456-65. PubMed ID: 19671802
[TBL] [Abstract][Full Text] [Related]
34. [What's new in dermatological treatments?].
Martin L
Ann Dermatol Venereol; 2010 Dec; 137 Suppl 4():S165-76. PubMed ID: 21193120
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
[TBL] [Abstract][Full Text] [Related]
36. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
Ferrándiz C; García A; Blasco AJ; Lázaro P
J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
[TBL] [Abstract][Full Text] [Related]
37. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
Gottlieb AB; Leonardi C; Kerdel F; Mehlis S; Olds M; Williams DA
Br J Dermatol; 2011 Sep; 165(3):652-60. PubMed ID: 21574983
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis.
Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B
Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386
[TBL] [Abstract][Full Text] [Related]
40. Ustekinumab for the treatment of moderate to severe psoriasis.
Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]